NCT06228066 2026-03-17
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
9 trialsNCT07155174 2026-03-17
SEZanne
AbbVie
Phase 2 Recruiting
NCT07459634 2026-03-10
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Jazz Pharmaceuticals
Phase 2 Not yet recruiting
NCT07328425 2026-01-12
ISG-TULIPS
Italian Sarcoma Group
Phase 2 Recruiting
NCT04607954 2026-01-06
Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT07258147 2025-12-02
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
Sichuan University
Phase 2 Not yet recruiting
NCT07121478 2025-10-01
Patients With High-grade Pancreatic Neuroendocrine Tumors
National Cancer Center, Korea
Phase 2 Enrolling by invitation
NCT05578326 2025-07-08
Study of Trilaciclib and Lurbinectidin
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT05800587 2025-04-04
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
Phase 2 Recruiting